HOXA9 and leukemia: CCI-006 treatment increased the levels of CHOP mRNA (Fig. 3d) and phosphorylated JNK (p-JNK) (Fig. 3a) and diminished the levels of HOXA9, MEIS1, and CMYC, important leukemogenic drivers and survival factors for MLL-r leukemia (Fig. 3e) in sensitive MLL-r leukemia cells [19–22].